Evidence map›Paper›PMID 41660655›Full record

ReviewKidney medicine2026

Glucose-only Therapy for Potassium Reduction: A Scoping Review.

Samuel Ford, Ian Coombes, Julian Williams, Claire Bertenshaw, Adam La Caze

Abstract readReview
In one paragraph

Review in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Samuel FordDepartment of Health and Behavioural Sciences, The University of Queensland, Brisbane, Australia.
Ian CoombesDepartment of Health and Behavioural Sciences, The University of Queensland, Brisbane, Australia.
Julian WilliamsDepartment of Medicine, The University of Queensland, Brisbane, Australia.
Claire BertenshawEmergency and Trauma Centre, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Adam La CazeDepartment of Health and Behavioural Sciences, The University of Queensland, Brisbane, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin-dextrose therapy is widely used to manage hyperkalemia but carries a significant risk of iatrogenic hypoglycemia. Glucose alone may reduce serum potassium by stimulating endogenous insulin release, potentially offering an insulin sparing alternative. This scoping review examined studies evaluating the effect of oral or intravenous glucose, without concurrent insulin, on serum or plasma potassium in adults. Nonhuman studies, nonpeer-reviewed sources, and studies where diabetes status could not be determined were excluded. Of 1,105 records screened, 30 met inclusion criteria. Most studies were small and conducted before 2,000, involving healthy individuals and patients with various conditions. A narrative synthesis was performed, with findings categorized by diabetes status and intervention type. Potassium responses varied: in nondiabetic individuals, glucose-only therapy generally lowered potassium, often to a clinically meaningful extent. In contrast, potassium often rose in insulin-dependent individuals. Methodological limitations were common, including small sample sizes, inconsistent statistical reporting, lack of control groups, and limited inclusion of hyperkalemic patients. Although glucose-only therapy may be effective in nondiabetic populations, evidence in people with diabetes is inconsistent and the evidence base is limited. Further rigorous, controlled studies are needed to clarify the role of glucose-only therapy in hyperkalemia management and its impact on hypoglycemia risk. Plain-language Summary Hyperkalemia, a condition where there is too much potassium in the blood, is often treated with insulin and glucose. But insulin can cause low blood sugar (hypoglycemia), which can be harmful. This review examined whether using glucose alone-without insulin-could lower potassium safely. We found that in people without diabetes, glucose-only therapy often lowered potassium. But in people with diabetes, the results were mixed and, in some cases, potassium levels increased. Most studies included in this review were small and had design limitations, highlighting the need for further research.

Indexed as

Diabetes mellituselectrolyte managementendogenous insulinglucose-only therapyhyperkalemiahypoglycemiainsulinpotassiumscoping reviewserum potassium

Identifiers

PMID41660655
PMCPMC12880623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.